Cargando…

Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model

Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and constitute up to 50% of intratumoral cells, making them highly appropriate therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreou, Tereza, Williams, Jennifer, Brownlie, Rebecca J, Salmond, Robert J, Watson, Erica, Shaw, Gary, Melcher, Alan, Wurdak, Heiko, Short, Susan C, Lorger, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957127/
https://www.ncbi.nlm.nih.gov/pubmed/33707311
http://dx.doi.org/10.1136/jitc-2020-001143
_version_ 1783664587382456320
author Andreou, Tereza
Williams, Jennifer
Brownlie, Rebecca J
Salmond, Robert J
Watson, Erica
Shaw, Gary
Melcher, Alan
Wurdak, Heiko
Short, Susan C
Lorger, Mihaela
author_facet Andreou, Tereza
Williams, Jennifer
Brownlie, Rebecca J
Salmond, Robert J
Watson, Erica
Shaw, Gary
Melcher, Alan
Wurdak, Heiko
Short, Susan C
Lorger, Mihaela
author_sort Andreou, Tereza
collection PubMed
description Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and constitute up to 50% of intratumoral cells, making them highly appropriate therapeutic delivery vehicles. Because myeloid cells are ubiquitously present in the body, we recently established a lentiviral vector containing matrix metalloproteinase 14 (MMP14) promoter, which is active specifically in tumor-infiltrating myeloid cells as opposed to myeloid cells in other tissues, and resulted in a specific delivery of transgenes to brain metastases in HSC gene therapy. Here, we used this novel approach to target transforming growth factor beta (TGFβ) as a key tumor-promoting factor in GBM. Transplantation of HSCs transduced with lentiviral vector expressing green fluorescent protein (GFP) into lethally irradiated recipient mice was followed by intracranial implantation of GBM cells. Tumor-infiltrating HSC progeny was characterized by flow cytometry. In therapy studies, mice were transplanted with HSCs transduced with lentiviral vector expressing soluble TGFβ receptor II–Fc fusion protein under MMP14 promoter. This TGFβ-blocking therapy was compared with the targeted tumor irradiation, the combination of the two therapies, and control. Tumor growth and survival were quantified (statistical significance determined by t-test and log-rank test). T cell memory response was probed through a repeated tumor challenge. Myeloid cells were the most abundant HSC-derived population infiltrating GBM. TGFβ-blocking HSC gene therapy in combination with irradiation significantly reduced tumor burden as compared with monotherapies and the control, and significantly prolonged survival as compared with the control and TGFβ-blocking monotherapy. Long-term protection from GBM was achieved only with the combination treatment (25% of the mice) and was accompanied by a significant increase in CD8+ T cells at the tumor implantation site following tumor rechallenge. We demonstrated a preclinical proof-of-principle for tumor myeloid cell-specific HSC gene therapy in GBM. In the clinic, HSC gene therapy is being successfully used in non-cancerous brain disorders and the feasibility of HSC gene therapy in patients with glioma has been demonstrated in the context of bone marrow protection. This indicates an opportunity for clinical translation of our therapeutic approach.
format Online
Article
Text
id pubmed-7957127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-79571272021-03-28 Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model Andreou, Tereza Williams, Jennifer Brownlie, Rebecca J Salmond, Robert J Watson, Erica Shaw, Gary Melcher, Alan Wurdak, Heiko Short, Susan C Lorger, Mihaela J Immunother Cancer Immune Cell Therapies and Immune Cell Engineering Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and constitute up to 50% of intratumoral cells, making them highly appropriate therapeutic delivery vehicles. Because myeloid cells are ubiquitously present in the body, we recently established a lentiviral vector containing matrix metalloproteinase 14 (MMP14) promoter, which is active specifically in tumor-infiltrating myeloid cells as opposed to myeloid cells in other tissues, and resulted in a specific delivery of transgenes to brain metastases in HSC gene therapy. Here, we used this novel approach to target transforming growth factor beta (TGFβ) as a key tumor-promoting factor in GBM. Transplantation of HSCs transduced with lentiviral vector expressing green fluorescent protein (GFP) into lethally irradiated recipient mice was followed by intracranial implantation of GBM cells. Tumor-infiltrating HSC progeny was characterized by flow cytometry. In therapy studies, mice were transplanted with HSCs transduced with lentiviral vector expressing soluble TGFβ receptor II–Fc fusion protein under MMP14 promoter. This TGFβ-blocking therapy was compared with the targeted tumor irradiation, the combination of the two therapies, and control. Tumor growth and survival were quantified (statistical significance determined by t-test and log-rank test). T cell memory response was probed through a repeated tumor challenge. Myeloid cells were the most abundant HSC-derived population infiltrating GBM. TGFβ-blocking HSC gene therapy in combination with irradiation significantly reduced tumor burden as compared with monotherapies and the control, and significantly prolonged survival as compared with the control and TGFβ-blocking monotherapy. Long-term protection from GBM was achieved only with the combination treatment (25% of the mice) and was accompanied by a significant increase in CD8+ T cells at the tumor implantation site following tumor rechallenge. We demonstrated a preclinical proof-of-principle for tumor myeloid cell-specific HSC gene therapy in GBM. In the clinic, HSC gene therapy is being successfully used in non-cancerous brain disorders and the feasibility of HSC gene therapy in patients with glioma has been demonstrated in the context of bone marrow protection. This indicates an opportunity for clinical translation of our therapeutic approach. BMJ Publishing Group 2021-03-11 /pmc/articles/PMC7957127/ /pubmed/33707311 http://dx.doi.org/10.1136/jitc-2020-001143 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Immune Cell Therapies and Immune Cell Engineering
Andreou, Tereza
Williams, Jennifer
Brownlie, Rebecca J
Salmond, Robert J
Watson, Erica
Shaw, Gary
Melcher, Alan
Wurdak, Heiko
Short, Susan C
Lorger, Mihaela
Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title_full Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title_fullStr Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title_full_unstemmed Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title_short Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
title_sort hematopoietic stem cell gene therapy targeting tgfβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
topic Immune Cell Therapies and Immune Cell Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957127/
https://www.ncbi.nlm.nih.gov/pubmed/33707311
http://dx.doi.org/10.1136/jitc-2020-001143
work_keys_str_mv AT andreoutereza hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT williamsjennifer hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT brownlierebeccaj hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT salmondrobertj hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT watsonerica hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT shawgary hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT melcheralan hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT wurdakheiko hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT shortsusanc hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel
AT lorgermihaela hematopoieticstemcellgenetherapytargetingtgfbenhancestheefficacyofirradiationtherapyinapreclinicalglioblastomamodel